Respin

Quick links to important sections

Respin

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Respin

Quick Facts

Property Description
Active ingredient Risperidone
Type (Class) Second-generation Antipsychotic (SGA)
Origin Synthetic, Benzisoxazole derivative
Primary Route Oral and Intramuscular (LAI)
General Purpose Stabilizing mood and thought processes

Respin: Classification and Active Composition

Respin is a synthetic prescription-only medicine containing the single active ingredient, Risperidone. It is officially classified as an Antipsychotic agent, specifically belonging to the Second-generation antipsychotic (SGA) subclass. This classification places it among compounds clinically recognized for their role in addressing major disruptions in perception and emotional stability. Risperidone itself is a Benzisoxazole derivative, a compound manufactured through synthesis to achieve its neurological effects.

The Atypical Mechanism and General Therapeutic Goal

The general therapeutic purpose of Respin is to stabilize and regulate abnormal thought patterns and emotional responses. It achieves this through its unique atypical mechanism of action, which involves a balanced antagonism of two major neurotransmitter receptors: Dopamine D2 and Serotonin 5HT2 receptors. This specific dual-receptor approach is a differentiating factor of the SGA class. The overall goal is to assist patients in achieving greater clarity in thinking and improved emotional stability, providing a crucial tool for management when processes like perception or mood become severely dysregulated.

Available Forms: Oral Preparations and Injectable Options

The active substance is manufactured into several pharmaceutical preparations to suit different protocols, which is a key differentiating factor in its use. These include standard tablets, an oral solution, and rapidly dissolving orally disintegrating tablets (ODT), all intended for oral administration. Crucially, the medication is also formulated as a long-acting injectable suspension (LAI), administered intramuscularly. This LAI option provides a unique advantage for ensuring continuous, sustained release of the active ingredient, helping to maintain stable therapeutic levels and simplifying the long-term management of care compared to daily oral dosing.

Regulatory References

  1. Risperidone (MedlinePlus)

What side effects are possible with Respin?

Possible side effects and safety information

The official safety profile for Respin (Risperidone) is organized by regulatory authorities to classify potential adverse reactions based on their frequency and the physiological system affected. Adverse reactions are grouped into categories from Very Common to Rare based on how often they occurred in clinical studies and post-marketing reports.


Frequency-Classified Effects

Classification Examples of Reactions
Very Common (ge 1 in 10 patients) Insomnia, Somnolence, Headache
Common (ge 1 in 100 to <1 in 10 patients) Parkinsonism, Dystonia, Akathisia, Weight increase, Hypotension, Nausea, Fatigue

Serious Safety Considerations

The regulatory label documents specific serious adverse reactions. These include Neuroleptic Malignant Syndrome (NMS) and Tardive Dyskinesia (TD), a condition involving involuntary movements. The label also notes the risk of metabolic changes, such as Hyperglycemia (high blood sugar) and Diabetes Mellitus, and potential Cerebrovascular Adverse Events (CVAEs).

Certain risks are related to duration or patient group. Extrapyramidal symptoms (EPS) may be more evident at the start of treatment or during dose escalation. The risk of TD generally increases with the duration of treatment.

Respin is not approved for use in older adults with dementia-related psychosis due to documented risks of increased mortality and CVAEs in this population. For children and adolescents, there is a noted risk of greater weight gain and hyperprolactinemia (elevated prolactin levels).

Overdose and Emergency Response

Overdose and When to Seek Help

This section describes the officially documented clinical manifestations of overdose for the active ingredient, Risperidone, and the emergency actions mandated by regulatory authorities.


Documented Overdose Manifestations and Risks

Classification Documented Signs and Outcomes
CNS Effects Drowsiness, sedation, extrapyramidal symptoms, and potential progression to coma or seizures.
Cardiovascular Risk Tachycardia, hypotension, and the critical risk of prolongation of the QT interval, which may lead to life-threatening arrhythmias.
Management Note Elderly patients and individuals with hepatic or renal impairment may be more susceptible to overdose effects.

Regulator-Mandated Emergency Actions

If overdose is suspected, regulatory documents strictly mandate that individuals seek immediate medical attention and contact emergency services or a poison control center.

Management is designated as symptomatic and supportive, as no specific antidote is known for Risperidone.

Due to the cardiac risks, continuous ECG monitoring is required in a hospital setting. Furthermore, official procedures advise securing the airway and considering decontamination methods like gastric lavage and activated charcoal, and explicitly recommend avoiding epinephrine and dopamine when treating hypotension.

Therapeutic Uses of Respin

What Respin Treats: Main Uses and Benefits

Respin is generally considered relevant for use in clinical settings to manage symptoms that interfere with daily functioning, specifically those associated with certain mental health and developmental conditions. It contributes to easing symptoms and supporting emotional stability. Its uses fall into three key areas of symptomatic management.

Supportive Management of Psychotic Symptoms and Mood Extremes

Respin is commonly used for managing symptoms associated with Schizophrenia in adults and adolescents, and acute manic or mixed episodes of Bipolar I Disorder. This symptomatic assistance is appropriate during phases where patients experience heightened emotional and physiological tension, manifesting as severe agitation, racing thoughts, and hyperactivity. The therapeutic benefit helps stabilize the patient's thinking and contributes to easing the overall symptom load.

Supportive Management for Severe Irritability

The medication is also applicable in pediatric and adolescent patients (aged 5+) with Autistic Disorder when symptoms cluster into patterns of challenging and disruptive behaviors. It is used specifically to manage the symptomatic interference of severe irritability, including episodes of aggression and temper tantrums. The benefit is to support the management of these behaviors, which in turn contributes to easing the overall symptom load and may support engagement in necessary behavioral therapies.

Quick Fact: Relief for Key Symptoms
Psychotic Symptoms Is used for managing hallucinations, delusions, and disorganized thinking.
Manic Symptoms May assist with moderating severe agitation, racing thoughts, and hyperactivity.
Behavioral Symptoms Plays a role in managing aggression, temper tantrums, and irritability.

Eligibility and Restrictions for Use

The eligibility for using Respin (risperidone) is strictly defined by official regulatory documentation, covering specific age groups, pre-existing conditions, and absolute contraindications.

Category Official Regulatory Status
Populations for whom use is allowed Adults with Schizophrenia or Bipolar I Mania. Adolescents (13+) with Schizophrenia. Children/Adolescents (10+) with Bipolar I Mania. Children/Adolescents (5+) with Irritability associated with Autistic Disorder.
Populations for whom use is contraindicated Patients with a known hypersensitivity or allergy to risperidone or any component of the formulation [1.1].

Eligibility-Related Restrictions

Category Regulatory Status
Absolute Contraindication Not Approved for use in elderly patients with dementia-related psychosis due to an increased risk of death and cerebrovascular events [1.4, 2.4].
Age-Related Exclusion The safety and effectiveness are not established below the minimum age thresholds for each approved condition (e.g., under 13 for Schizophrenia; under 5 for Autistic Irritability) [1.1, 3.1].
Organ Function Use in patients with severe renal or hepatic impairment is restricted, requiring a lower initial dose and slower titration [2.2, 2.4].
Reproductive Status The medication is excreted into human milk, leading to the official recommendation that breastfeeding should not occur. Neonates exposed during the third trimester may be at risk of extrapyramidal and/or withdrawal symptoms [2.4, 3.1].

Regulatory documents define who can and cannot use the medicine by establishing three clear boundaries: absolute prohibition for hypersensitivity and dementia-related psychosis; conditional, restricted use for specific comorbidities like severe organ impairment or cardiovascular disease; and clear age-based thresholds below which the safety profile is officially designated as not established.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Respin is strictly defined by changes in drug exposure and combined clinical effects as documented in regulatory labeling. The medicine should be used with caution in combination with several substance classes.

Pharmacokinetic Interactions (Metabolic)

Interactions primarily involve the body’s CYP2D6 and CYP3A4 enzyme systems, which affect plasma concentrations of the active antipsychotic fraction.

  • Concentration Increase: Strong CYP2D6 inhibitors, such as Fluoxetine and Paroxetine, are documented to increase the overall plasma concentration of Respin.
  • Concentration Decrease: Strong CYP3A4 inducers, including Carbamazepine, are documented to decrease the plasma concentration of the active fraction.

Pharmacodynamic Interactions (Additive Effects)

Interactions that cause combined clinical effects are also officially noted:

  • Central Nervous System (CNS) Depressants: Co-administration with other centrally-acting drugs or alcohol can result in additive CNS effects, such as enhanced drowsiness. Avoidance of alcohol is advised.
  • Hypotensive Agents: The blood pressure-lowering effect of other drugs may be enhanced due to the alpha-blocking activity of Respin.
  • Dopamine Agonists: The clinical effects of Levodopa and other dopamine agonists may be officially antagonized.

Specific Population & Combination Notes

Regulatory documents include specific warnings for certain combinations:

  • A higher incidence of mortality was observed with concomitant use of Furosemide in elderly patients with dementia-related psychosis.
  • Reduced starting doses are recommended for patients with Renal or Hepatic impairment due to expected decreased clearance of the active moiety.

Mechanism of Action

How Respin Works: Mechanism of Action

Respin exerts its action by reversibly inhibiting the Vesicular Monoamine Transporter 2 (VMAT2) protein, which is integral to nerve endings in both the central and peripheral nervous systems. This targeted inhibition blocks the necessary intracellular transport of monoamine neurotransmitters, such as norepinephrine and dopamine, from the cell cytoplasm into storage vesicles. Consequently, the neurotransmitters are rapidly degraded by enzymes, leading to the depletion of releasable monoamine stores at the nerve terminal. The resultant decrease in available norepinephrine primarily dampens sympathetic nerve signaling to peripheral organs. This modulation of the sympathetic system leads to a physiological consequence that includes a slowing of the heart rate and vasodilation (widening) of blood vessels. Furthermore, VMAT2 inhibition affects central dopamine and serotonin storage, influencing pathways that modulate movement and emotional processing.

Dosage and Administration Information

How to Use Respin

Respin (risperidone) is administered via oral and injectable routes, with the specific form dictating the usage schedule. The medication is available as standard tablets, oral solution, and orally disintegrating tablets (ODT) for daily use, or as a long-acting injectable (LAI) suspension for periodic administration.


Standard Dosing and Frequency

Administration is highly dependent on the condition being managed. For oral use in adults, the starting dose for Schizophrenia is typically 2 mg/day, escalating to a recommended maintenance range of 4 mg to 8 mg/day. Daily dosing may be taken once or twice daily. For acute Bipolar Mania, the starting dose is 2 mg to 3 mg/day, with a maximum dose of 6 mg/day.

Injectable Use: The long-acting injectable (LAI) formulation is typically given as an intramuscular (IM) injection every 2 weeks by a healthcare professional. Upward dose adjustments for the LAI should not be made more frequently than every four weeks.


Administration Requirements and Special Populations

Intake Conditions: Oral forms may be taken with or without food. If using the oral solution, it may be mixed with water, coffee, orange juice, or low-fat milk, but must not be mixed with cola or tea. ODTs should be placed immediately on the tongue and not split or chewed.

LAI Protocol: The initiation of the LAI requires mandatory oral antipsychotic coverage for the first three weeks following the initial injection, due to the delayed release of the active ingredient.

Dose Adjustment: Lower starting doses of 0.5 mg twice daily are utilized for older adults and patients with severe renal or hepatic impairment, with slower dose titration intervals. For pediatric patients using the oral solution or tablets for Autistic Irritability, dosing is weight-based, starting at 0.25 mg/day or 0.5 mg/day.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Respin

Research Evidence for Schizophrenia Management

Respin was studied to explore symptom patterns in Schizophrenia, a condition characterized by fluctuating or episodic manifestations. The evidence landscape includes multiple short-term (4-to-8 week) randomized controlled trials (RCTs) that research examined to explore initial outcomes related to systemic or functional imbalance. Longer-term maintenance trials studies explored how symptoms change over time and focused on outcomes related to relapse or recurrence frequency in adults and adolescents. Studies reported measurements of overall symptom severity compared to placebo. Comparative evidence is lacking for the long-acting injectable (LAI) versus oral form in real-world settings, and long-term effects are not fully established regarding functional recovery.


Research Evidence for Acute Manic and Mixed Episodes

Respin was studied for symptoms related to acute manic or mixed episodes in Bipolar I Disorder, a condition involving periods of heightened symptoms. The research primarily consists of short-term RCTs, typically lasting 3 to 6 weeks, which research examined to track outcomes capturing phases of heightened symptom activity in adults and children/adolescents. The medicine was evaluated in two main research scenarios: as monotherapy and as adjunctive therapy with mood stabilizers. Findings indicate changes measured during the acute treatment period compared to those receiving placebo. The existing research highlights a focus on monitoring symptom change in the acute manic or mixed phase, but there is limited information for long-term outcomes related to exploring the recurrence of depressive episodes.


Research Evidence for Managing Irritability in Autistic Disorder

For children and adolescents with Autistic Disorder, Respin was studied for exploring symptom change in outcomes linked to inflammatory or irritative states, specifically severe irritability, aggression, and temper tantrums. The evidence includes short-term (8-to-12 week) placebo-controlled RCTs used in research exploring how symptoms change over time in the pediatric population (ages 5 to 17). Studies reported measurements on the Aberrant Behavior Checklist (ABC) Irritability subscale compared to placebo. Data for certain groups remain insufficient, particularly for applying these findings to the adult population with Autistic Disorder.

Frequently Asked Questions (FAQ)

Common questions about Respin (FAQ)

Q: How quickly does Respin usually start to affect the body?

A: Official studies indicate that initial changes may be seen within the first one to two days of starting the oral form. However, a more significant benefit is typically observed after the first week of treatment. For the long-acting injectable (LAI) formulation, oral medication is required for the first three weeks until the full release of the active ingredient begins.

Q: What happens if I miss taking a dose of Respin?

A: According to patient instructions in regulatory documents, if a dose is missed, it can be taken as soon as it is remembered. If the next scheduled dose is almost due, the instruction is to skip the missed dose and not take two doses together.

Q: Are there any long-term effects of using Respin that are commonly discussed?

A: Regulatory warnings note that the risk of developing certain long-term movement disorders, such as Tardive Dyskinesia (TD), generally increases with the time a patient uses the medication. Other commonly documented effects for long-term monitoring include metabolic changes, such as changes in weight, blood sugar levels, and blood cholesterol.

Q: How long does Respin typically stay in your system after stopping?

A: The active substance and its primary active metabolite are generally cleared from the body over a period of several days after stopping the daily oral form. For the long-acting injectable, the medicine is designed to be released and cleared over a period spanning several weeks to more than a month.

Q: Are there warnings about driving or operating machinery while on Respin?

A: The official label includes warnings that this medication may cause impairment in judgment, thinking, and motor skills, including drowsiness or dizziness. The label notes the potential for impairment, which may affect a person's ability to drive a car or operate complex machinery.

Q: Is Respin available in a generic version?

A: Yes, the active ingredient in Respin, known as risperidone, is available as a generic medicine. The generic version comes in various forms, including oral tablets and long-acting injections.

Q: What should be done if someone accidentally takes too much Respin?

A: The official safety instructions direct patients to contact the local poison control center or emergency medical services if an accidental overdose is suspected. This guidance is in place to ensure prompt professional help is received.

Q: Is it necessary to take Respin at the same exact time every day?

A: While the dosage instructions permit taking the medicine once or twice daily, it is generally advised to take the dose at approximately the same time each day. This practice helps to maintain a consistent level of the medicine in the body, which is important for management.

Q: What is the common age range of people prescribed Respin?

A: Respin is approved for use across a wide age range, including adults with Schizophrenia and Bipolar Mania. It also has specific approvals for children and adolescents: aged 5 and older for Irritability associated with Autistic Disorder, and adolescents aged 13 and older for Schizophrenia.

Q: Is Respin used for other conditions besides its primary approved use?

A: Regulatory documents list the approved uses as the treatment of Schizophrenia (acute and maintenance), acute manic or mixed episodes associated with Bipolar I Disorder, and Irritability associated with Autistic Disorder. Official information only pertains to these approved uses.

Q: Do you need a special diet while taking Respin?

A: The oral forms of Respin can be taken with or without food. Official guidance specifically states that if using the oral solution, it should not be mixed with cola or tea. However, it may be mixed with water, coffee, orange juice, or low-fat milk.

Q: Is Respin known to cause weight gain or loss?

A: In clinical studies documented in official labels, weight increase is listed as a Common adverse reaction. Because of this potential change, official warnings recommend monitoring for changes in weight throughout treatment.

Q: Is Respin considered a type of antidepressant or anxiety medication?

A: No, Respin is officially classified as a Second-generation Antipsychotic (SGA) agent. Its approved uses are primarily for conditions involving major disruptions in thought patterns or severe mood dysregulation, such as Schizophrenia and Bipolar I Disorder.

Q: What is the difference between Respin and other similar medications people mention?

A: Respin belongs to the group of medicines known as atypical or Second-generation Antipsychotics. This classification distinguishes it from older drugs because its mechanism of action involves balancing the activity of two key chemical messengers in the brain: Dopamine D2 and Serotonin 5HT2 receptors.

Q: Does Respin affect sleep patterns or energy levels?

A: Official adverse reaction lists include both Somnolence (drowsiness) and Insomnia (difficulty sleeping) as Very Common effects. Fatigue is also listed as a Common effect, indicating that changes to both sleep and general energy levels are possible.

Q: Why do some people say they felt worse before feeling better on Respin?

A: The official label notes that certain side effects, such as drowsiness or movement issues, may appear early in treatment, sometimes before the full intended benefit is achieved. The full therapeutic effect of the medicine may take several weeks to develop.

Q: What type of monitoring is often needed when starting Respin?

A: Because of the potential for the drug to cause metabolic changes, official guidance recommends monitoring for symptoms of hyperglycemia (high blood sugar) and periodically checking weight and blood lipid (fat and cholesterol) levels at the start of and throughout treatment.

Q: What is the general success rate of Respin reported in clinical trials?

A: Clinical trials measure outcomes by comparing symptom severity scores in patients taking Respin versus those taking an inactive placebo. Examples of these measurements include tracking changes in overall symptom severity for Schizophrenia or measuring changes in specific behaviors, such as irritability in Autistic Disorder.

Q: Can I drink coffee or caffeine while taking Respin?

A: Official instructions for the oral solution state that it can be mixed with coffee. While there are no specific regulatory warnings prohibiting general caffeine consumption, it is important to note the drug itself can cause CNS effects like insomnia or drowsiness.

Q: Does Respin impact fertility or reproductive health?

A: Official warnings note that the medicine can lead to elevated levels of the hormone prolactin (hyperprolactinemia). Elevated prolactin levels may potentially interfere with the menstrual cycle and ovulation in females.

Q: Are there different forms or strengths of Respin available?

A: Yes, Respin is manufactured in multiple forms. These include standard oral tablets, an oral solution, orally disintegrating tablets (ODT), and a long-acting injectable suspension. These forms are offered in a range of strengths to accommodate different dosing protocols.

Q: Are there any known differences in how Respin affects men versus women?

A: Official documents highlight the risk of elevated prolactin levels, which may manifest differently in males and females. For example, hyperprolactinemia can potentially lead to menstrual irregularities in women and sexual dysfunction in men.

Q: How long does the primary effect of a single Respin dose typically last?

A: The duration of effect is reflected in the official dosage instructions, which recommend taking the oral medicine once or twice a day. This schedule is designed to maintain consistent and therapeutic levels of the drug in the body over approximately a 24-hour period.

Q: Why is Respin described as a 'novel' or 'unique' medication?

A: Respin belongs to the class of medications known as atypical antipsychotics. Its unique status comes from its balanced action: it works by interacting with both the Dopamine D2 and Serotonin 5HT2 receptors in the brain.

Q: Does Respin cause any digestive system issues?

A: Official documents list several digestive-related side effects. These include Nausea and Constipation, both of which are classified as Common adverse reactions reported in studies.

Q: Is Respin used for acute or chronic conditions?

A: Respin is officially indicated for the management of both acute and chronic conditions. Examples of acute use include the short-term treatment of manic or mixed episodes, while maintenance treatment for Schizophrenia represents a chronic use.

How should Respin be stored and disposed of?

How to Store and Dispose of Respin

Respin (risperidone) must be stored according to official regulatory specifications to maintain its integrity. The medication should be kept at controlled room temperature, typically between 15°C and 25°C (59°F and 77°F). It is mandatory to keep the product from freezing and protect it from both light and excessive moisture. The medicine must remain in its original, tightly closed container.

All forms of Respin must be stored in a location inaccessible to children. Unused or expired medication should be disposed of by taking it to an authorized drug take-back program. If no take-back program is available, the drug must be mixed with an undesirable substance, sealed in a bag, and discarded in the household trash, in accordance with local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Respin found in:

A-Z Index: